Results 31 to 40 of about 633,523 (228)

Fluoroquinolones as HIV-1 integrase, topoisomerase I and II inhibitors.

, 2023
Fluoroquinolones as HIV-1 integrase, topoisomerase I and II inhibitors.
Kulsoom Ghulam Ali (14992580), Zohaib Raza (9186430), Ameer Fawad Zahoor (10728633), Samreen Gul Khan (14992577), Asim Mansha (1290051), Rabia Akhtar (14992574), Shagufta Kamal (13565544)   +6 more
core   +1 more source

Prevalence of resistance mutations associated with integrase inhibitors in therapy-naive HIV-positive patients in Hungary [PDF]

, 2021
Widespread introduction of HIV integrase inhibitors into clinical care may result in appearance of drug resistance mutations affecting treatment outcome.
Szlávik János, Minárovits János, Lakatos Botond, Mezei Mária, Pocskay Ágnes, Áy Éva   +5 more
core   +3 more sources

Therapeutic Opportunities in Infectious Diseases: Highlights from the Society of Medicines Research Symposium, held on March 14th 2013 at the National Heart & Lung Institute, London, UK [PDF]

, 2013
Collingwood, S P, Pryde, D C, Anderson, RJ, Collingwood, SP, Pryde, DC, Anderson, Rosaleen, Alderton, W K, Alderton, WK   +7 more
core   +6 more sources

Emergence of the G118R Pan-Integrase Resistance Mutation as a Result of Low Compliance to a Dolutegravir-Based cART

Infectious Disease Reports, 2022
HIV-1 resistance towards integrase inhibitors is a potential threat of the success of HIV-1 combination treatment. G118R is a rare drug resistance mutation conferring pan-integrase resistance.
Helene Mens, Lasse Fjordside, Jannik Fonager, Jan Gerstoft   +3 more
doaj   +1 more source

Discovery of Novel Integrase Inhibitors Acting outside the Active Site Through High-Throughput Screening

Molecules, 2019
Currently, an increasing number of drugs are becoming available to clinics for the treatment of HIV infection. Even if this targeted therapy is highly effective at suppressing viral replication, caregivers are facing growing therapeutic failures in ...
Cindy Aknin, Elena A. Smith, Christophe Marchand, Marie-Line Andreola, Yves Pommier, Mathieu Metifiot   +5 more
doaj   +1 more source

Uncommon pathways of immune escape attenuate HIV-1 integrase replication capacity [PDF]

, 2012
An attenuation of the HIV-1 replication capacity (RC) has been observed for immune-mediated escape mutations in Gag restricted by protective HLA alleles.
Olvera, A., Markle, T.J., Cheung, P.K., John, M., Brumme, Z.L., Brumme, C.J., Carlson, J.M., Kelleher, A.D., Markowitz, M., Frahm, N., McGovern, R., Harrigan, P.R., Brander, C., Heckerman, D., Sanchez, J., Walker, B.D., Chopera, D.R., Sela, J., Le, A.Q., Jessen, H., Martin, E., Rosenberg, E., Brockman, M.A., Mallal, S.   +23 more
core  

Characterization of HIV-1 Integrase Gene and Resistance Associated Mutations Prior to Roll out of Integrase Inhibitors by Kenyan National HIV-Treatment Program in Kenya [PDF]

, 2020
BACKGROUND: Antiretroviral therapy containing an integrase strand transfer inhibitor plus two Nucleoside Reverse Transcriptase inhibitors has now been recommended for treatment of HIV-1-infected patients.
Lihana Raphael, Sepha, Mabeya, Nyerere Andrew, Nyamache Anthony, Ngugi Caroline   +4 more
core   +1 more source

Optical Detection of Cellular Signals at Material Interfaces

Advanced Healthcare Materials, EarlyView.
Emerging functional materials are transforming optical detection of cellular signals. This review highlights optical techniques that exploit the unique optical properties of diverse materials to detect and quantify cellular electrical, chemical, and mechanical signals, and discusses key opportunities and challenges.
Xuchen Ren, Jitong Ren, Zixin Zhang, Koney Eungkon Kim, Francis L. Hong, Yuecheng Peter Zhou   +5 more
wiley   +1 more source

HIV-1 resistance patterns to integrase inhibitors in Chilean patients with virological failure on raltegravir-containing regimens

Journal of Virus Eradication, 2020
In this viewpoint we would like to describe our results in terms of resistance pattern in Chilean patients with virological failure (VF) on raltegravir (RAL)-containing-regimens and highlight the need for the concomitant availability of genotypic ...
Pablo Ferrer, Consuelo Rodriguez, Alicia Sciaraffia, Rocío Tordecilla, Veronica Ramos, Magdalena Durán, Carlos Beltrán, Alejandro Afani   +7 more
doaj   +1 more source

The Natural Product Corramycin Acts as a DNA Gyrase Poison and Overcomes Fluoroquinolone Resistance in Mycobacterium tuberculosis

Advanced Science, EarlyView.
Corramycin, a myxobacterial natural product antibiotic, exhibits potent bactericidal activity against multidrug‐resistant Mycobacterium tuberculosis. The compound hijacks bacterial transporters such as BacA and OppABCD to enter the cell and inhibits DNA synthesis through a previously unrecognized mode of DNA gyrase poisoning, locking the enzyme in an ...
Franziska Fries, Jennifer Herrmann, Michael Dal Molin, Yaëlle Wormser, Timo Risch, Yunsheng Gao, Gareth Prosser, Francesca Gubellini, Ariel Mechaly, Joshua B. Wallach, Anthony Castro, Arka Banerjee, Sari Rasheed, Alexander Horn, Mathias Müsken, Michael Kurz, Lindsay Sonnenkalb, Viola Dreyer, Stefan Niemann, Sönke Andres, Dirk Schnappinger, Uli Kazmaier, Norbert Reiling, Rolf Müller, Jan Rybniker, Stéphanie Petrella   +25 more
wiley   +1 more source